Izo Hello all, I want to share one of my top stock picks. Say hello to the new generation of breast cancer detection.
To all potential investors in IZO, I wanted to share a little write up I made to outline the progress this company has made to allow you to decide if IZO should be the next addition to your portfolio. Sitting with a $41 Million market cap and under 40 M shares outstanding, IZO is about to take the breast imaging industry to a whole new level. Not only is it going to save the life of the females in our lives but it is also going to dominate a 5.4 (2025) billion dollar industry. Traditional Mammograms miss 1 in 5 breast cancers due to false negative test results. When mammograms do detect a tumor/lesion, the abnormality is typically 11mm in size, with IZO’s Breast CT we have proven to detect abnormalities at 3-5 mm in our clinical trials. What this means is we are detecting the cancer 0.93 - 1.5 years earlier over traditional mammography. This will catch the cancer before it metastasizes greatly increasing survival rates. Fast forward to today, we have extensive ongoing trials displaying the dominance of our machine in the industry, collecting data that will only increase our chances of an expedited FDA approval process. A step we have ahead of all of our competitors is the fact that our machine doesn’t require the painful breast compression. If you compare our tech with some of the giants in the business, you’ll find all the others still require painful compression. With Starfish medical (Canada’s largest medical device designer) helping us to design and manufacture our commercial Breast CT device, with Anita Nosratieh Ph.D, a former lead reviewer where she worked with companies seeking approval of breast cancer screening and diagnostic devices, and with Dr. Craig Abbey, a scientific reviewer for the FDA developing and presenting our study designs for the FDA, I think we have an amazing chance at a successful and potentially expedited FDA run. Here is a quote from Starfish Medicals founder and CEO Scott Phillips “"We have worked with numerous companies in the medical and breast imaging spaces. Izotropic has conducted significant technical, clinical and market-positioning efforts that provide a high level of confidence that the final product will meet patient, physician and marketplace requirements.”
Today we are in stage 5 of 10 in our FDA approval process, about to enter stage 6. We have met with the FDA and presented our studies and designs, now we are waiting (literally any day now) for our written feedback to launch into our clinical and non-clinical testing. IZO has already been scouting clinical partners to expedite our process.
We just hired a rockstar team (on top of the team that got us to where we are today), to get our word and product out there, with over 31% insider & management ownership, and the float tightening more and more every day, getting in around this $1.00-$2.00 level is an absolute steal as a long term investment. I can see this going upwards of $10.00 a share in approx 1-2 years time. Good luck and thanks for reading.